Navigation Links
Experimental Gel May Help Those With Advanced Parkinson's
Date:4/18/2012

By Denise Mann
HealthDay Reporter

WEDNESDAY, April 18 (HealthDay News) -- A gel form of two common Parkinson's drugs delivered via a feeding tube-like device may help people with advanced disease reduce medication side effects and possibly avoid brain surgery.

That's the report from researchers who found the experimental levodopa-carbidopa intestinal gel works better than a standard pill regimen in reducing "off" time in people with advanced Parkinson's disease.

About 1 million people in the United States are living with Parkinson's disease, a progressive movement disorder marked by tremor, slowness and/or rigidity. The disease slowly destroys the nerve cells in the brain that produce the chemical dopamine, which controls muscle movement.

Treatment with oral levodopa-carbidopa -- brand names include Sinemet, Sinemet CR and Parcopa -- helps replace dopamine levels, but higher doses and long-term use of the oral drugs can cause troublesome side effects, including spontaneous and involuntary movements (dyskinesias) or "off" times.

The new gel is infused through a portable pump connected to a gastric tube that feeds the small intestine. "Pills have a shorter half-life, but delivering the medication via gel allows for more continuous delivery and repairs the brain levels in a more normal way," said study author Dr. C. Warren Olanow, a professor of neurology and neuroscience at the Mount Sinai School of Medicine, in New York City. As a result, "you have less 'off' time and less dyskinesia," he added.

While not a cure for the disease, the method is an important step forward, Olanow said. "It's a proof of concept that when you deliver the medication continuously, you get a better response without worsening dyskinesia," he noted.

And the new gel "may also have applications in early Parkinson's disease to help people avoid the side effects that come from long-term continuous use of these medications," he added.

The study was released April 17 and will be presented next week at the American Academy of Neurology's annual meeting in New Orleans.

In his study, 71 participants received either the continuous infusion of the gel and inactive placebo pills or an inactive gel and pills that contained levodopa-carbidopa. When the three-month study began, the average participant had Parkinson's disease for about 11 years and experienced 6.6 hours of "off" time every day.

Those who received the gel reduced their "off" time by about nearly two extra hours per day and their "on" time -- or time spent without movements -- increased by an average of two hours per day, compared to those who took levodopa and carbidopa in pill form, the researchers reported. The most common side effects with the gel were related to complications inserting the device, abdominal pain, pain during the procedure and nausea.

The plan is submit the current data to the U.S. Food and Drug Administration for approval. The study was supported by Abbott Laboratories, the company developing the new intestinal gel.

"It sounds like a good option for people with advanced Parkinson's disease," said Dr. Roy Alcalay, an assistant professor of neurology at Columbia University Medical Center in New York City, and an adviser for the Parkinson's Disease Foundation. "The indications are similar to those of the brain surgery [known as deep brain stimulation], and may be good for people who do not want the surgery or those who still have a lot of symptoms and medication side effects after surgery," he said.

"The drug seems to work well, but the major concern with the drug is the problems around its administration, which include an abdominal procedure done by a gastroenterologist," he added.

Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

Learn more about Parkinson's disease at the Parkinson's Disease Foundation .

SOURCES: Roy Alcalay, M.D., assistant professor of neurology, Columbia University Medical Center, New York City; Warren Olanow, M.D., professor of neurology and neuroscience, Mount Sinai School of Medicine, New York City; presentation, American Academy of Neurology, annual meeting (April 21-28, 2012), New Orleans


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Pill for Multiple Sclerosis Shows Promise
2. Experimental Chemo Combo for Colon Cancer Disappoints
3. Experimental Pill May Ease Multiple Sclerosis Disability
4. Experimental Drug Shows Promise Against Cushings Disease
5. Experimental Drug Offers Hope for Rare Bone Disease: Study
6. Experimental Drug Shows Promise Against Type 2 Diabetes
7. First-in-human drug for malignant glioma available in experimental trial
8. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
9. Experimental Drugs Do Battle Against Advanced Prostate Cancer
10. Experimental Blood Thinner Given Before Surgery Shows Benefit
11. Wolfson Foundation awards £20 million to UCL for experimental neurology center
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Gel May Help Those With Advanced Parkinson's 
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology: